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Fragile X syndrome (FXS) is the first cause of inherited intellectual disability, due to the silencing of the X-linked Fragile X
Mental Retardation 1 gene encoding the RNA-binding protein FMRP. While extensive studies have focused on the cellular
and molecular basis of FXS, neither human Fragile X patients nor the mouse model of FXS—the Fmr1-null mouse—have been
profiled systematically at themetabolic and neurochemical level to provide a complementary perspective on the current, yet
scattered, knowledge of FXS. Using proton high-resolution magic angle spinning nuclear magnetic resonance (1H HR-MAS
NMR)-based metabolic profiling, we have identified a metabolic signature and biomarkers associated with FXS in various
brain regions of Fmr1-deficient mice. Our study highlights for the first time that Fmr1 gene inactivation has profound, albeit
coordinated consequences in brain metabolism leading to alterations in: (1) neurotransmitter levels, (2) osmoregulation, (3)
energymetabolism, and (4) oxidative stress response. To functionally connect Fmr1-deficiency to its metabolic biomarkers, we
derived a functional interaction network based on the existing knowledge (literature and databases) and show that the FXS
metabolic response is initiated by distinct mRNA targets and proteins interacting with FMRP, and then relayed by numerous
regulatory proteins. This novel ‘‘integratedmetabolome and interactomemapping’’ (iMIM) approach advantageously unifies
novel metabolic findings with previously unrelated knowledge and highlights the contribution of novel cellular pathways
to the pathophysiology of FXS. These metabolomic and integrative systems biology strategies will contribute to the
development of potential drug targets and novel therapeutic interventions, which will eventually benefit FXS patients.
[Supplemental material is available for this article.]
Fragile X syndrome (FXS) is the most frequent cause of inherited
intellectual disability (ID) and the most commonly identified ge-
netic cause of autism (Chelly et al. 2006; Gecz et al. 2009). FXS
affects 1 in4000males and1 in 7000 femalesworld-wide (Hagerman
2008) and is caused by the silencing of the X-linked Fragile X
Mental Retardation 1 (FMR1) gene positioned in Xq27.3. In FXS
patients, a dynamic mutation increasing abnormally the number
of CGG repeats in the first exon of the FMR1 gene leads to their
hypermethylation and the subsequent absence of its gene product,
FMRP (Penagarikano et al. 2007). Although a monogenic disorder,
FXS is a disease of complex etiology accompanied by behav-
ioral (hyperactivity, autism), neurological (susceptibility to epi-
leptic seizures), as well as physical abnormalities (macroorchidism,
elongated face, hyperextensible finger joints) (Penagarikano et al.
2007). A mouse model of FXS knock-out (KO) for the murine ho-
molog of FMR1, has been generated, exhibiting learning and be-
havioral abnormalities that recapitulate the human phenotype
(The Dutch-Belgian Fragile X Consortium 1994). The absence of
FMRP induces abnormal extra dendritic spines in neurons of FXS
patients and Fmr1-KO mice that represent the synaptic defect
underpinning the ID (Bassell and Warren 2008; Swanger and
Bassell 2011). At the molecular level, FMRP is an RNA-binding
protein controlling translation as a component of neuronal
messenger ribonucleoprotein (mRNPs) particles associated with
somatic and synaptic polyribosomes (Khandjian et al. 2004;
Davidovic et al. 2006). FMRP is involved in localized synaptic
translation, an essential mechanism that controls protein syn-
thesis locally at the synapse to shape dendritic spines (Bassell and
Warren 2008). FMRP and its network of mRNA targets and inter-
acting proteins (Khandjian et al. 2005; Bardoni et al. 2006) con-
tribute to several forms of synaptic plasticity involved in learning
andmemory processes and notably induced by activation of type I
metabotropic glutamate receptors (Do¨len and Bear 2008). Al-
though perturbations of these neurospecific events involving
FMRP represent the molecular basis of the cognitive impairments
observed in FXS patients and Fmr1-KOmice, the pathophysiology
of FXS remains poorly understood. Since FMRP modulates protein
synthesis via direct regulation of the translation of multiple
mRNAs, we hypothesize that Fmr1-deficiency could functionally
affect protein interaction networks with direct consequences on
signaling cascades and cellular metabolism.
To investigate this hypothesis, we performed a comprehen-
sive profiling of the metabolome of the Fmr1-deficient brain. In
order to connect Fmr1-deficiency to its metabolic phenotypes, we
developed an integrative systems biology approach to map meta-
bolic markers of Fmr1-deficiency directly onto the interactome.
8Corresponding authors.
E-mail davidovic@ipmc.cnrs.fr.
E-mail m.dumas@imperial.ac.uk.
Article published online before print. Article, supplemental material, and pub-
lication date are at http://www.genome.org/cgi/doi/10.1101/gr.116764.110.
2190 Genome Research
www.genome.org
21:2190–2202  2011 by Cold Spring Harbor Laboratory Press; ISSN 1088-9051/11; www.genome.org
 Cold Spring Harbor Laboratory Press on December 1, 2011 - Published by genome.cshlp.orgDownloaded from 
Metabonomics is a powerful systems biology approach capturing
the variation in low-molecular weight compounds in organs or
biofluids in response to pathophysiological interventions or ge-
netic modifications (Nicholson et al. 2002). Metabolic profiling
methods, such as protonnuclearmagnetic resonance spectroscopy
(1H NMR) or mass spectrometry, in conjunction with multivariate
pattern recognition analyses, are highly effective in understanding
disease processes and drug responses in humans and model or-
ganisms (Nicholson et al. 2002), particularly in the case of meta-
bolic diseases (Dumas et al. 2006, 2007). In neuroscience, 1H-NMR
metabonomic analysis was used to characterize the neurochemical
and metabolic profile of bipolar disorder patients (Lan et al. 2009)
and transgenic models of neurological disorders of genetic origin,
such as spinal cerebellar ataxia, Huntington’s disease, or Batten’s
disease (Pears et al. 2005; Holmes et al. 2006), as well as Rett Syn-
drome, the major cause of profound ID in girls (Viola et al. 2007).
Hypothesis-free metabolic profiling provides genome-scale meta-
bolicmodeling strategies particularly suitable to analyze genotype-
phenotype correlations following gene inactivation in animal
models of human diseases, in metabolic Quantitative Trait Locus
(mQTL) mapping (Dumas et al. 2007) studies or in metabolic ge-
nome-wide association studies (Illig et al. 2010). Mapping meta-
bolic biomarkers onto biological networks enhances the un-
derstanding of complexmetabolic signatures at the pathway level,
as typically performed by metabolite-set enrichment analysis
(MSEA) (Xia and Wishart 2010; Pontoizeau et al. 2011).
Here we developed a novel alternative strategy which is based
on mapping metabolic phenotypes directly onto protein-protein
interaction (ppi) networks and analyzing the topology of the
resulting network to identify key proteins involved in generating
themetabolic phenotype associated in Fmr1-deficiency. This novel
methodology is particularly suited for studying FXS since Fmr1-
deficiency directly affects protein networks, and ppi networks are
used to unravel the molecular etiology of complex diseases
(Navratil et al. 2010, 2011).
In this study, we present the first comprehensive metab-
olomic profiling of the Fmr1-deficient brain in the mouse, using
proton high-resolution magic-angle spinning (1H HR-MAS) NMR-
based metabonomics, which is particularly suited for small tissue
samples analysis. We then define a robust metabolic phenotype
(metabotype) of FXS in cerebellum, cortex, striatum, and hippo-
campus of its mouse model. To understand how Fmr1-deficiency
mechanistically generates its associated metabolic signature, we
present a novel integrative strategy, which we call integrated
metabolome and interactome mapping (iMIM), connecting FMRP
to its metabolic endpoints via protein-protein interaction networks.
Concomitantly, we have used network metrics to identify pivotal
proteins or FMRP mRNA targets of the network generating the
metabotype associated with Fmr1-deficiency and further confirmed
their biological relevance in vivo. This novel integrative systems bi-
ology strategy highlights the role of key regulatory pathways in FXS
pathogenesis, explaining the complexity of the FXS metabotype. In
general, iMIM anchors the regulation of complex metabolic phe-
notypes in protein interaction networks and signaling cascades.
Results
Definition of the optimal spatiotemporal coordinates
for metabotyping of the Fmr1-deficient brain
We first assessed the patterns of expression of Fmr1, the defective
gene in FXS, byWestern blot and immunohistochemistry to define
the optimal spatiotemporal coordinates for metabotyping the de-
veloping brain of Fmr1-deficient mice (Fig. 1). Western blot anal-
ysis of total brain extracts at different post-natal ages reveals that
the Fmr1 gene product, FMRP, is abundantly expressed during the
first two post-natal weeks of life, peaking at 5–12 d. Then, FMRP
expression strongly decreases as the animal ages to reach lower
levels during adulthood (Fig. 1A). These data are consistent with
a study reporting a peak of expression of FMRP in thehippocampus
and cerebellum during the second post-natal week of life (Lu et al.
2004). To refine the brain regions that express the highest levels
of FMRP, we performed immunolabeling on brain sections from
12-d-old wild-type (WT) mice. A strong immunoreactivity was
detected in the whole brain (Fig. 1B), particularly in four brain
regions: cerebellum, cortex, hippocampus, and striatum (Fig.1C),
which manifest dysfunction in FXS patients and Fmr1-KO mice
(Penagarikano et al. 2007). We, therefore, studied the metabolic
consequences of Fmr1-deficiency by 1HHR-MASNMRprofiling at
this defined post-natal age when FMRP is strongly expressed (Fig. 1).
The choice of this specific post-natal age appears also particularly
relevant since morphological and physiological defects in the brain
of Fmr1-KO mice may appear transiently and are often detected in
the second post-natal week of life (Nimchinsky et al. 2001; Larson
et al. 2005; Bureau et al. 2008; Cruz-Martin et al. 2010), corre-
sponding to the critical timewindowof active synaptogenesis in the
brain. In addition, we restricted our analysis to males to avoid sex-
bias in the assessment of FXS metabolic phenotype.
Figure 1. Expression of FMRP in post-natal brain. (A) Western blot
analysis of FMRP expression in total brain extracts (25 mg/lane) at various
post-natal stages and in adult (Ad.). (B) Immunohistochemistry on 12-d-old
mouse brain longitudinal sections reveal a strong expression of FMRP
(brown) in the whole brain and in specific regions (C ), such as cortex
(ctx), hippocampus (hip), striatum (str) and cerebellum (crb). Nuclei
were counterstained with cresyl-violet.
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Identification of metabolic signature of Fmr1-deficiency
in mouse brain regions
To derive a metabolic signature associated with FXS, we compared
metabolic profiles from intact brain tissues originating from 12-d-
old wild-type and Fmr1-null male mice (n = 10 for each genotype).
Compared to classical 1H NMR spectroscopy, generally used to
profile liquid tissue extracts, proton high-resolution magic-angle
spinning NMR spectroscopy was developed to directly profile in-
tact tissues while preserving cellular integrity—this is particularly
suited for characterization of mass-limited samples such as the
mouse hippocampus. Supervised multivariate statistical modeling
using orthogonal partial least-squares discriminant analysis (OPLS-
DA) enables a significant discrimination between Fmr1-deficient
and control brain regions (Fig. 2). Remarkably, the OPLS-DA three-
dimensional (3D) score plot (Fig. 2A) shows thatWT brain samples
segregate at the periphery of the model, reflecting the anatomical
and functional differences between these brain regions also de-
scribed in the adult rat brain (Tsang et al. 2005). Conversely, Fmr1-
null mouse brain regions all tend to project toward a common
central area in the model. In fact, WT brain regions have a distinct
metabolic phenotype whereas Fmr1-null brain regions are more
alike; this is suggestive of a relatively undifferentiated metabolic
state in Fmr1-null brains. Interestingly, cortex and cerebellum
display remarkably parallel responses to Fmr1-deficiency, sugges-
tive of similar metabolic signatures, whereas striatum and hippo-
campus display unique metabolic signatures (Fig. 3; Table 1). We
then compared the respective effects of Fmr1-deficiency (KO vs.
WT) and of region (ctx vs. crb) on metabolic profiles in an OPLS-
based variance components (VC)model (Fig. 2B), showing that the
metabolic variation originating from anatomic region (explaining
up to 89% of metabolic variation for myo-inositol, as measured by
the signal at d3.62) is larger than the genetic variation (up to 36%
of ethanolamine variation, d3.83).
The metabolic signature associated with each brain region is
derived from model coefficients obtained from a series of pair-
wise OPLS-DA models segregating KO from WT for each brain
region (Fig. 3) and shows the existence of brain region-specific
metabotypes associated with Fmr1-deficiency (Table 1). We report
here for the first time that, although FMRP is neither an enzyme
nor a receptor directly involved in neurotransmittermetabolismor
signaling, Fmr1-deficiency has dramatic impacts on the levels of
six neurotransmitters (gamma-amino butyric acid [GABA], gluta-
mate, acetylcholine [Ach], taurine, alanine, and aspartate) and
several of their precursors or catabolites (glutamine, acetate, cho-
line, and N-acetyl aspartate [NAA]) (Table 1). The Fmr1-deficient
metabotypes also involve the osmolyte and the secondary mes-
sengers precursor myo-inositol, intermediary metabolites and
lipids totally unrelated to neurotransmission (acetoacetate, lactate
and carbonyls from fatty acids). At the network level, 25 metabo-
lites undergo significant alterations in the Fmr1-null brain (Table 1)
and may be considered as global FXS biomarkers.
Metabolite Set Enrichment Analysis (MSEA)
of Fmr1-deficiency metabotypes
A Metabolite-Set Enrichment Analysis (MSEA) (Xia and Wishart
2010), an extension of the Gene Set Enrichment Analysis (GSEA)
(Subramanian et al. 2005), was then used to test for metabolic
pathways enrichment in each brain region. In the cortex, Fmr1-
deficiency is significantly associated with: an increase in lipid-
oxidized species (mainly carbonyls, such as CH3-CH2-CH2-CO-
and -CH2-CO-) and acetoacetate, and a decrease in GABA and
glutamate, their precursor, glutamine, as well as in N-acetyl-as-
partate (NAA) and lactate (Table 1). The decreased cortical levels of
glutamine corroborate a previous study using reversed-phase high-
performance liquid chromatography (HPLC) (Gruss and Braun
2001) on Fmr1-KO and WT cortex, and we confirmed, using an
enzymatic assay, that the cortical levels of glutamate were signifi-
cantly decreased in Fmr1-KO animals (P = 0.011) (Fig. 4A). In ad-
dition, the increase in carbonyl groups that we observe in the
cortex was previously documented using a biochemical approach
(El Bekay et al. 2007). These data strongly support the robustness of
1H HR-MAS NMR to identify metabolic changes in Fmr1-deficient
brain. Subsequent MSEA analysis (Xia and Wishart 2010) high-
lights that significant cortical alterations in glutamine/glutamate
metabolism, in synthesis and degradation of ketone bodies, as well
as in glutathione metabolism derive from this metabotype (Sup-
plemental Table S1). In the cerebellum, decreases in glutamine,
GABA, NAA, myo-inositol (whereas its stereoisomer scyllo-inositol
is increased), aspartate, and acetate associated with increases in
both Ach and its precursor, choline (Table 1), correlate with sig-
nificant alteration in glycerophospholipid and b-alanine metabo-
lism (Supplemental Table S1). Interestingly, the reduced glutamine
levels in Fmr1-deficient cerebellum were also detected by others
(Gruss and Braun 2001), and we have been able to confirm by
Figure 2. Metabolic signature of Fmr1-deficiency in 12-d-old brain. The
metabolic variation observed in 1H NMR spectra acquired in 12-d-old
mouse brain samples was modeled using an orthogonal partial least
square-discrimination analysis (OPLS-DA). PLS components maximizing
the segregation of the groups are computed. Each PLS component
corresponds to a combination of the initial 1H NMR spectral variables,
known asmodel coefficients or loadings. Each individual spectrum has new
coordinates on the PLS components, known as scores. As a consequence,
the three-dimensional OPLS-DA scores plot (A) segregates the different
sample groups according to brain region (shapes) and Fmr1-deficiency
status (white and black shapes). (B) OPLS variance component model of
cortex and cerebellum. (Ctx) cortex, (crb) cerebellum, (hip) hippocampus,
(str) striatum, (ko) Fmr1-knockout, (wt) wild-type samples.
Davidovic et al.
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ELISA a significant decrease in GABA cerebellar concentrations in
Fmr1-KO animals (P = 0.038) (Fig. 4B). The hippocampus displays
increases in taurine, creatine, and myo-inositol that evoke alter-
ations in taurine/hypotaurine metabolism and inositol phosphate
metabolism (Table 1; Supplemental Table S1). Of particular in-
terest, increased taurine levels were also reported in hippocampus
of Fmr1-KO animals by a previous study (Gruss and Braun 2001).
Finally, in the striatum, a decrease in kynurenine (Table 1) drives
significant alterations of tryptophan metabolism (Supplemental
Table S1), coupled to decreases in alanine, creatine, and adenine.
Integrated metabolome and interactome mapping
of FMR1-deficiency metabotypes
To bring a mechanistic understanding in our genotype-phenotype
associations and functionally connect the causal mutation in the
FMR1 gene with the downstream metabolic biomarkers derived
from the OPLS-DA models presented
above, we developed a novel network bi-
ology strategy—integrated metabolome
and interactomemapping. Databases and
literature data sets were gathered to re-
construct a molecular interaction net-
work (see Supplemental Table S2 for
an exhaustive list of sources, and see
Methods for detailed construction of the
interactome) encapsulating (1) known
and putative mRNAs regulated by FMRP
resulting from either large-scale screen-
ings or individual characterization of
direct RNA-protein interactions, (2) the
known FMRP protein-protein interact-
ome, including kinases, and (3) meta-
bolic (KEGG database) (Kanehisa et al.
2008) and neuronal signaling pathways
(NeuronDB, Yale University). Since our
iMIM approach uses databases with hu-
man annotations, we chose to standard-
ize and use the official human gene and
protein symbols in the related para-
graphs, even though proteins or mRNA
interactors might have been identified
in a variety of organisms. The topology of
the resulting integrated metabolome in-
teractomemapping network was then ana-
lyzed to visualize functional paths between
FMRP and its associated metabotypes
and to model how inactivation of FMR1
propagates through the cellular network
until it reaches its metabolic endpoints
(Fig. 5A). Considering a givenmetabolite
M and using the Ockham’s razor princi-
ple, the shortest path between FMRP and
M through the interactome network
is likely to provide a mechanistic link
between FMR1-deficiency and its con-
sequence on metabolite M. Since FMRP
is neither an enzyme nor a receptor, the
shortest path between FMRP and M be-
comes: FMRP ! interacting protein or
mRNA-target ! enzyme (or receptor) !
metabolite M, where the shortest path
length (spl) is 3. The spl becomes 2 in the case of a receptor or en-
zyme being an interacting protein or mRNA target. The average spl
computed from the entire knowledge network between FMRP and
the 25metabolites identified as FXSmarkers by NMR is 3.38, which
approaches 3, meaning that FMRP is connected to a perturbed
metabolite via one of its mRNA targets or protein partners, which in
turn will interact with a receptor or enzyme. This spl is significantly
lower than the average spl obtained from randomly resampled lists
of 25 biomarkers with 100,000H0 iterations (spl = 3.38, P = 0.03427)
(Fig. 5B), which confirms that FMR1-deficiency is selectively con-
nected to the perturbed metabolites identified above.
Centrality-based stratification of proteins in the iMIM network
using pivotal betweenness
Based on the iMIM network and the set of all shortest paths, we
then assessed the centrality of a given protein or mRNA-target
Figure 3. Region-specific metabolic signature of Fmr1-deficiency in 12-d-old brain. Metabolic variations in
1HNMRspectraobtained from Fmr1-null andwild-typemicewereassessed independently for eachbrain region
by OPLS-DA. These OPLS-DA models are represented as a pseudo-spectrum. Positive model coefficients cor-
respond to highermetabolite concentrations in KOanimals, whereas negativemodel coefficients are associated
with higher metabolite concentrations in WT animals. Metabolic signature as obtained from cortex (Q2Yhat =
0.61) (A), cerebellum (Q2Yhat = 0.57) (B), hippocampus (Q
2Yhat = 0.84) (C ), and striatum (Q
2Yhat = 0.44) (D).
Metabolomics and systems biology of FXS
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between FMR1-deficiency and its metabolic endpoints by esti-
mating their pivotal betweenness (PB). PB is a measure of cen-
trality, meaning that graph edges used by several shortest paths
will have a high PB (see Methods; Table 2; Supplemental Table S3).
This continuous variable is directly correlated to the weight of
the proteins in the shortest paths of the network and enables
a systematic stratification and ranking of these proteins based on
their relative importance at the network scale. The iMIM network
derived from themetabolic signature of FXS highlights that among
the 30 most pivotal proteins, 13 are either FMRP protein inter-
actors, such as the protein FXR2P (PB = 8.23 3 106) (Zhang
et al. 1995), the homolog of FMRP, or are encoded bymRNA targets
of FMRP (Fig. 5), such as themRNA encoding super oxide dismutase
1 (SOD1, PB = 1.35 3 105) (Bechara et al. 2009), amyloid beta
precursor protein (APP, PB = 1.56 3 105) (Westmark and Malter
2007), calcium/calmodulin-dependent protein kinase II alpha
(CAMK2A, PB = 7.93 3 106) (Iacoangeli et al. 2008), eukaryotic
translation elongation factor 1 alpha 1 (EEF1A1, PB = 6.063 106)
(Sung et al. 2003), and microtubule-associated protein 1B
(MAP1B, PB = 3.93 3 106) (Brown et al. 2001; Chen et al. 2003;
Lu et al. 2004; Iacoangeli et al. 2008). Interestingly, poorly char-
acterized putative mRNA FMRP targets, such as the mRNA
encoding the small GTP-ase and cytoskeleton-regulator RHOA (PB
= 1.83 3 105) (Chen et al. 2003) and the calcium regulatory
protein Calbindin1 (CALB1, PB = 1.35 3 105) (Miyashiro et al.
2003), appear as pivotal in our network (Table 2; Fig. 5); RHOA
connects FMRP to four of the perturbedmetabolites, while CALB1
relays FMRP to metabolic perturbations of the osmolyte and sec-
ondary messenger myo-inositol (Fig. 5).
Biological confirmation of the in vivo association of FMRP
with mRNA encoding pivotal proteins of the iMIM network
The pivotal FMRP mRNA targets highlighted in silico by the iMIM
network were initially identified in large-scale screenings for FMRP
mRNA targets, and some still lack extensive biological validation.
We, therefore, sought to further confirm that FMRP physically
interactswith iMIM-derived pivotalmRNA targets in vivo (Fig. 5A),
using UV-crosslinking and immunoprecipitation assays (CLIP)
(Ule et al. 2005). Compared to classical immunoprecipitation, the
CLIP approach uses UV-crosslinking irradiation of tissues to gen-
erate covalent bonds between nucleic acids and proteins, thereby
preserving the labile interaction between mRNA and proteins that
are often lost in classical immunoprecipitation. Immunoprecipi-
tation of FMRP mRNA complexes was carried out using the R60
polyclonal antibody raised against the C terminus of FMRP on
Fmr1-WTand KO total P12 brain extracts (See Supplemental Fig. S1
for exhaustive characterization of the R60 antibody). As expected,
FMRP was not detected in input or immunoprecipitate from Fmr1-
KO animals, whereas it was recovered in WT input and immuno-
precipitate (Fig. 6A). In addition, two known interactors of FMRP,
its homologues FXR1P and FXR2P (Zhang et al. 1995), present in
equal levels in the Fmr1-KO and WT input, are only recovered in
the WT immunoprecipitate (Fig. 6A), confirming the specificity of
the immunoprecipitation. RT-PCR analysis of mRNAs extracted
from Fmr1-WT and KO input and immunoprecipitates was then
carried out (Fig. 6B). The equal intensity of the bands corre-
sponding to the studied mRNAs reveal that Mtap1b, Tubb3, Sod1,
Rhoa, and Calb1mRNAs are expressed at similar levels in the input
fraction from Fmr1-KO and WT brain (Fig. 6B). Fmr1 mRNA was
detected in WT input and immunoprecipitate (Fig. 6B, lanes
2,4), together with the known mRNA target of FMRP encoding
Table 1. Metabolic signature of Fmr1-deficiency
Fmr1-KO
metabotypes
Brain region Component
ctx crb hip str Genetic Region
Lactate Y Y Y
Glutamine Y Y Y
GABAa Y Y Y [
N-acetyl-aspartate Y Y Y Y
Glutamatea Y Y
Acetotacetate [
CH2-CO [
CH2-CH2-CH2-CO [
Myo-inositol Y [
Aspartatea Y
Acetate Y Y
Acetylcholinea [ [
Choline [ [
Scyllo-inositol [
N,N,N trimethyl lysine Y
Taurinea [ [
Creatine [ Y
Alaninea Y Y
Beta-amino butyrate [
Kynurenine Y
N-alpha acetylornithine Y
Adenine Y
Inosine [
Purine [ [
Ethanolamine Y
Metabotypes derived from Figures 2 and 3 are summarized for each
model, by brain regions (OPLS-DA models) (Fig. 3) or by using variance
components (factors: genetic or region) (Fig. 2B). (Ctx) cortex, (crb)
cerebellum, (hip) hippocampus, (str) striatum.
aNeurotransmitters.
Figure 4. Quantification of glutamate levels in cortical extracts and
GABA levels in cerebellar extracts of Fmr1-KO brain vs. WT. Glutamate
cortical (A) and GABA cerebellar concentrations (B) are significantly re-
duced in Fmr1-KO extracts compared to WT (P = 0.011; P = 0.038, re-
spectively; n = 9 for each genotype).
Davidovic et al.
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microtubule-associated protein 1B, Mtap1b (Fig. 6A, lane 4), cor-
roborating previous studies (Lu et al. 2004; Iacoangeli et al. 2008).
Conversely, no amplicon corresponding to the unrelated mRNA
encoding beta-Tubulin 3 (Tubb3) was detected in either immuno-
precipitate. Similar results were obtained with another negative
control—themRNA encoding phosphoglycerate kinase 1 (Pgk1, not
shown)—thereby confirming the specificity of the approach.
Interestingly, the mRNA Sod1 was detected in the WT immuno-
precipitate (Fig. 6B, lane 4), showing for the first time its in vivo
association with FMRP in brain. Also, the mRNA Rhoa and Calb1
encoding pivotal proteins of the network were also specifically re-
covered in the Fmr1-WT immunoprecipitates (Fig. 6B, lane 4). Al-
together, these data confirm the association of FMRPwith Rhoa and
Calb1mRNAs suggested byhigh-throughput screening and strongly
support the fact that these mRNAs are in vivo targets of FMRP.
Identification of perturbed pathways in Fmr1-deficient brain
Further GSEAs (Subramanian et al. 2005) were carried out on the
iMIMnetwork’s pivotal proteins to identify significantly perturbed
pathways in Fmr1-null mouse brain. GSEA was performed by com-
paringGeneOntology (Rivals et al. 2007) (Supplemental Table S4) and
KEGG (Kanehisa et al. 2008) (Supplemental Table S5) annotations of
the pivotal proteins (n = 257) to those of the entire set of proteins
present in the iMIMnetwork. Typical enriched terms fromGSEAshow
that the metabolic signature of the FXS mouse model translates into
perturbations of ‘‘central nervous system development,’’ ‘‘signaling,’’
and ‘‘function and metabolism,’’ among which were alterations of
‘‘glutamate signaling pathways,’’ ‘‘protein kinase cascade,’’ ‘‘actin
cytoskeleton organization and biogenesis,’’ and ‘‘synaptic trans-
mission’’ coupled to ‘‘behavior and learning andmemory defects.’’
Discussion
Although FXS is a monogenic disorder, Fmr1-deficiency genotype/
phenotype associations are difficult to assess from a mechanistic
point of view, since FMRP is involved in the translation of nu-
merousmRNAs and affects the levels of proteins involved in a wide
range of cellular processes (Darnell et al. 2005). This conceptual
difficulty required the development of a novel integrative systems
biology method to mechanistically understand the metabolic
consequences of Fmr1-deficiency. In this study, we profiled the
metabolome of the brain of the mouse model of FXS using 1H HR-
MAS NMR spectroscopy, to gain knowledge on FXS metabolism.
We then developed the integrated metabolome and interactome
mapping framework and its associated network metric, the pivotal
betweenness. This strategy allowed us to get new insight into FXS
pathophysiology and to identify key FMRPmRNA targets involved
in regulating its metabolic phenotype, as discussed in detail below.
Comprehensive metabolic profiling of the brain of the mouse
model of FXS: Identification of Fmr1-deficiency metabolic
phenotypes specific to each brain region
Using 1H HR-MAS NMR spectroscopy-based metabolic profiling,
we show that the absence of FMRP affects the metabolic pheno-
type of the developing brain in a region-specific manner, with
cortex and cerebellum being the most affected regions. In the wild
type, each brain region has a unique metabolic profile, which
translates into a clustering of the samples according to brain region
in the OPLS-DA 3D scores plot (Fig. 2A). This is suggestive of re-
gion-specific functions and metabolisms even at this early post-
natal age and corroborates a previous metabolomic study on adult
rat brain (Tsang et al. 2005). This clustering becomes considerably
less evident in the Fmr1-deficient brain, where samples are pro-
jected toward the center of the model in a more homogenous
manner. The incompletemetabolic differentiation observed in the
Fmr1-deficient brain might be related to the general delayed mat-
uration of the Fmr1-KO brain suggested by the immature-looking
dendritic spines in Fragile Xmice andhumanpatients (Nimchinsky
et al. 2001; Larson et al. 2005; Bureau et al. 2008; Cruz-Martin et al.
2010), but it is also directly linked to the functional consequences
Figure 5. Interactome-mapping of FMR1-deficiency metabotype. (A) FMR1 integrated metabolome and interactome mapping (iMIM) network. The
metabolites significantly affected in the different models (Table 1) weremapped onto the interactome, using FMRPmRNA targets and protein interactors,
KEGGmetabolic pathways, and neurotransmitter/receptor databases. The resulting network allows connecting of the causal gene FMR1 to the downstream
metabolic consequences of its deficiency. Pivotal shortest paths via enzymes and receptors are represented in blue and green, respectively. (B) Statistical
validation of the FMR1 knowledge network under the null hypothesis (H0). The average shortest path length (spl) between FMR1 and the biomarker
metabolites (n = 25) was computed and compared to the distribution of average spl obtained after 100,000 H0 network simulations (i.e., networks obtained
after 100,000 random selections of 25 metabolites from the entire metabolic network). This simulation under the null hypothesis shows that FMR1 appears
significantly connected to the candidate biomarker metabolites, with an average distance of 3.38 hops (n = 100,000 random simulations, P = 0.03427).
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of the absence of FMRP and the interactions with its mRNA targets
and protein partners. However, the events leading to this spine
dysgenesis in FXS appear to be a complexmix of abnormal nervous
system early development (Callan and Zarnescu 2011), delayed
maturation (Bureau et al. 2008; Cruz-Martin et al. 2010), and al-
tered stabilization and pruning (Swanger and Bassell 2011), FMRP
being involved in each of these processes via regulation of its
mRNA targets and protein partners. This illustrates that the ob-
served delayed maturation of the Fmr1-deficient brain and the
lack of Fmr1 function cannot be completely disentangled. This
prompted us to use novel integrative systems biology approaches
to explore the functional consequences of Fmr1-deficiency on
metabolism.
Identification of metabolic pathways perturbed
by Fmr1-deficiency
To investigate how Fmr1-deficiency results in themetabotypes that
we detected in the brain of the mouse model of FXS, we first ap-
plied a recent integrative systems biology strategy, testing which
metabolic pathways are significantly affected—metabolite-set en-
richment analysis (MSEA) (Xia andWishart 2010; Pontoizeau et al.
2011; Supplemental Table S1). This analysis contributed to the
identification of the principal metabolic pathways perturbed in
the brain of the mouse model of FXS.
Fmr1-deficiency drives alterations in neurotransmitters levels
Our results show that FXS brain undergoes global alterations in
neurotransmitter metabolism, mainly glutamate, GABA, acetyl-
choline, and taurine. In the Fmr1-deficient cortex, the reduction of
glutamine and glutamate metabolism we observe might result in
a reduction of the amounts of released glutamate, with important
consequences on the functioning of cortical circuitry and cortical
excitability, as previously reported (Gibson et al. 2008). In Fmr1-
deficient mice, the reduced mRNA levels of Gad1, encoding the
glutamate-decarboxylase Gad65 that catalyzes the conversion of
glutamate into GABA (D’Hulst et al. 2009) (Fig. 7), may explain the
decreased cortical and cerebellar GABA levels. Given the essential
role of GABA for the development of cortex and cerebellum, lower
GABA levels might perturb optimal development of these struc-
tures, especially at 11–12 d old, a stage which encompasses the
time windowwhenGABA shifts from excitatory toward inhibitory
effects, as reported in rat (Ben-Ari et al. 2007). On the other hand,
our data suggest that the Fmr1-deficient hippocampus undergoes
increased neuronal inhibition mediated by taurine during early
post-natal development (El Idrissi and Trenkner 2004). Finally,
a decrease in acetylcholine and its precursor, choline, suggests
a disruption of the cholinergic system in the Fmr1-deficient cere-
bellum (Fig. 7), which plays an essential developmental role in this
region (De Filippi et al. 2005). In conclusion, the delicate balance
between excitatory and inhibitory inputs appears compromised
Table 2. Top 30 pivotal proteins derived from interactome mapping of Fmr1-deficiency metabotypes
Rank
Human gene
accession number
Official
protein
symbol Full protein name Reference
Pivotal
betweenness
1 ENSG00000067560 RHOAa Ras homolog gene family, member A (Chen et al. 2003) 1.83 3 105 *
2 ENSG00000075651 PLD1 Phospholipase D1, phosphatidylcholine-specific 1.79 3 105 *
3 ENSG00000198805 PNP Purine nucleoside phosphorylase 1.59 3 105 *
4 ENSG00000142192 APPa Amyloid beta (A4) precursor protein (Westmark and Malter 2007) 1.56 3 10-5 *
5 ENSG00000142168 SOD1a Superoxide dismutase 1, soluble (Bechara et al. 2009) 1.35 3 105 *
6 ENSG00000104327 CALB1a Calbindin 1, 28 kDa (Miyashiro et al. 2003) 1.35 3 105 *
7 ENSG00000133731 IMPA1 Inositol(myo)-1(or 4)-monophosphatase 1 1.35 3 105 *
8 ENSG00000087085 ACHE Acetylcholinesterase 1.12 3 105 *
9 ENSG00000129245 FXR2a Fragile X mental retardation, autosomal homolog 2 (Zhang et al. 1995) 8.23 3 106 *
10 ENSG00000070808 CAMK2Aa Calcium/calmodulin-dependent protein kinase II alpha (Iacoangeli et al. 2008) 7.93 3 106 *
11 ENSG00000070748 CHAT Choline O-acetyltransferase 7.86 3 106 *
12 ENSG00000113580 NR3C1a Glucocorticoid receptor, group C, member 1 (Miyashiro et al. 2003) 7.45 3 106 *
13 ENSG00000094755 GABRPa Gamma-aminobutyric acid (GABA) A receptor, pi (Miyashiro et al. 2003) 6.73 3 106 *
14 ENSG00000187730 GABRDa Gamma-aminobutyric acid (GABA) A receptor, delta (Miyashiro et al. 2003) 6.73 3 106 *
15 ENSG00000076685 NT5C2 59-nucleotidase, cytosolic II 6.73 3 106 *
16 ENSG00000196839 ADA Adenosine deaminase 6.73 3 106 *
17 ENSG00000156508 EEF1A1a Eukaryotic translation elongation factor 1 alpha 1 (Sung et al. 2003) 6.06 3 106
18 ENSG00000081760 AACS Acetoacetyl-CoA synthetase 5.64 3 106
19 ENSG00000114353 GNAI2a Guanine nucleotide binding protein, alpha
inhibiting activity polypeptide 2
(Miyashiro et al. 2003) 4.88 3 106
20 ENSG00000104951 IL4I1 Interleukin 4 induced 1 4.49 3 106
21 ENSG00000104951 AKT1S1 AKT1 substrate 1 (proline-rich) 4.49 3 106
22 ENSG00000104951 NUP62 Nucleoporin 62 kDa 4.49 3 106
23 ENSG00000128050 PAICS Phosphoribosylaminoimidazole carboxylase 4.49 3 106
24 ENSG00000140443 IGF1R Insulin-like growth factor 1 receptor 4.37 3 106
25 ENSG00000198931 APRT Adenine phosphoribosyltransferase 4.35 3 106
26 ENSG00000171105 INSR Insulin receptor 4.19 3 106
27 ENSG00000118689 FOXO3a Forkhead box O3 (Brown et al. 2001) 4.11 3 106
28 ENSG00000131711 MAP1Ba Microtubule-associated protein 1B (Brown et al. 2001; Darnell et al.
2001; Chen et al. 2003)
3.92 3 106
29 ENSG00000131067 GGT7 Gamma-glutamyltransferase 7 3.78 3 106
30 ENSG00000141510 TP53 Tumor protein p53 3.43 3 106
Proteins involved in the interaction network (Fig. 5) were ranked by pivotal betweenness (PB). Accession numbers for the genes encoding these pivotal
proteins are provided in the table. Asterisks indicate PB values that appear in the 5% quantile of the PB values distribution.
aProteins directly interacting with FMRP or encoded by FMRP mRNA targets; corresponding reference provided in brackets.
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in the mouse model of FXS at this early post-natal stage corre-
sponding to the time-window of synaptogenesis, with direct
consequences on neuronal circuits formation development
(Akerman and Cline 2007).
Altered osmolyte and secondary messengers balance
In the Fmr1-deficient brain, we observed variations in osmolytes
such as NAA,myo-inositol, and taurine. Osmolytes control the ion
gradient across membranes, and modifications of their levels may
facilitate neuronal discharge and epileptiform activity (Liu et al.
2008), as described in the Fmr1-deficient mouse (Qiu et al. 2008).
In addition, disruption of osmolyte balance is widely observed
in various neurological conditions, and constitutes a hallmark of
brain dysfunctions (Pears et al. 2005; Viola et al. 2007; Lan et al.
2009). Alternatively, decreased myo-inositol levels in the hippo-
campus and increased levels in the cerebellum of Fmr1-deficient
mice suggest dysregulations of phosphoinositide metabolism
since myo-inositol is a precursor for these important secondary
messengers. Our findings support the idea that Fmr1-deficiency
might modify neuronal physiology in a nonspecific manner,
through osmoregulation and secondary messenger signaling
machinery.
Disruption of post-natal energy metabolism and neuron/glia metabolic
cooperation in the FXS brain
Astrocytes and neurons cooperate metabolically for neuronal en-
ergy fueling and biosynthesis of neurotransmitters (Fig. 7). In the
Fmr1-deficient brain, the decreased levels of lactate in cerebellum
and cortex and the increase in the ketone-body acetoacetate in
cerebellum might reflect a disruption of neuronal metabolic fuel-
ing during post-natal brain development. These metabolites are
the essential source of neuronal energy, thus replacing glucose at
this specific period to replenish acetyl-coA stores to fuel the tri-
carboxylic acids (TCA) cycle (Pellerin 2008) (Fig. 7). Glutamate and
GABA can also enter the TCA cycle via conversion upstream or
downstream via the intermediate metabolite alpha-ketoglutarate
(aKG) (Fig. 7). Altered glutamine, glutamate, and GABA levels also
support a disruption of the interplay between glia and neurons
controlling the glutamine–glutamate–GABA cycle (McKenna 2007)
(Fig. 7). Our results highlight the readjustment of TCA cycle and
energy metabolism in neurons and glial cells in the absence of
FMRP.
Adaptative response to increased oxidative stress
We have identified a marked increase in cortical oxidative stress
markers, such as lipid peroxidation products, notably aldehydes
and carbonyls species. These species result from free radical attack
of unsaturated lipids by superoxide anions, normally detoxified by
SOD1. We previously observed this specific metabotype in sod1-
deficient Caenorhabditis elegans (Blaise et al. 2007). Interestingly,
we have shown that FMRP binds in vitro Sod1 mRNA and that its
absence decreases the cortical levels of SOD1 (Bechara et al. 2009),
a pivotal protein in our network (Table 2; Figs. 5, 6). Here, we have
shown the association of FMRP with Sod1mRNA in vivo (Fig. 6B).
These data directly correlate depletion of SOD1 to biochemical and
enzymatic markers of enhanced oxidative stress in the brains of
Fmr1-deficient mice (increase in carbonyl groups in the cortex (El
Bekay et al. 2007; this study). These data indicate that increased
oxidative stress is a phenotypic trait of FXS.
Development of the iMIM framework and associated network
metrics to identify key FMRP targets involved in regulating
its metabolic phenotype
iMIM and pivotal betweenness
FMRP is a translational regulator and has no direct link with me-
tabolism, apart from SOD1. However, it interferes with protein-
protein interaction networks via regulation of the levels of the
proteins encoded by its mRNA targets. To investigate the Fmr1-
deficiency metabolic phenotype/genotype association, we de-
veloped a new approach, which we called integrated metabolome
and interactome mapping. In iMIM, the metabolic markers asso-
ciated with Fmr1-deficiency were mapped onto metabolic path-
ways and protein-protein interaction networks (Fig. 5; Table 2).
Close analysis by GSEA of the most significantly enriched bi-
ological functions in the resulting network shows that the meta-
bolic perturbations in the brains of Fmr1-deficient mice are asso-
ciated with various biological processes typically related to CNS
and neuron development, cognitive functions, signal transduc-
tion, and neurotransmitter metabolism (Supplemental Tables S4,
S5). To identify the key proteins related to these processes thatmay
link Fmr1-deficiency consequences to metabolism, we analyzed
the network topology by estimating the pivotal betweenness of
Figure 6. Fmr1, Mtap1b, Sod1, Rhoa, and Calb1 mRNAs interact with
FMRP in vivo. (A) Western blot analysis of UV-crosslinking and immuno-
precipitation (CLIP) assay performed on Fmr1 wild-type (WT) and knock-
out (KO) total brain lysates using polyclonal antibodies raised against the
C terminus of FMRP. Input lysate (1/100th) and immunoprecipitates (IP,
1/20th) were probed for FMRP and its interacting protein partners FXR1P
and FXR2P, respectively, by western blotting, revealing the presence of
FMRP in the WT immunoprecipitates (upper panel revealed with 1C3
antibody), together with interacting partners FXR1P and FXR2P (lower
panel revealed by 3Fx antibody). (B) RT-PCR analysis of mRNAs associated
with FMRP. Total RNA was extracted from the input brain lysate and
immunoprecipitates described in A, and used as a template for RT-PCR.
RT-PCR products obtained from Fmr1-KO (lane 1) andWT (lane 2) inputs
and from immunoprecipitates of Fmr1-KO (lane 3) and WT (lane 4)
brain extracts were separated and visualized by agarose gel electro-
phoresis. This reveals that the known FMRP mRNA targets Fmr1 and
Mtap1B are selectively recovered in the WT immunoprecipitate, while
the unrelated mRNA Tubb3 is not recovered. Sod1 mRNA is also selec-
tively recovered in the immunoprecipitate together with Rhoa and Calb1
mRNAs. Control PCR (lane 5) was performed in the absence of reverse-
transcriptase. Lower DNA molecular weight markers presented on the
left of the gels are, respectively, 100, 200, 300, 400, 500, 600, 800, and
1000 bp.
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each protein of the network. We defined this network metric to
enable a systematic stratification and ranking of the proteins based
on their relative importance at the network scale (Fig. 5; Table 2;
Supplemental Tables S3, S4). Among the 30 pivotal proteins of the
network, 13 are encoded by putative or confirmedmRNA targets of
FMRP. To confirm the biological relevance of the identified key
regulatory proteins, we validated in vivo the association of FMRP
in brain with their corresponding mRNA, notably Sod1, Rhoa, and
Calb1 (Fig. 6B), thereby ascertaining the robustness of our approach.
Identification of key FMRP mRNA targets and proteins and pathways
involved in FXS
The two principal branches of the network involve two proteins
encoded by the confirmed mRNA target of FMRP APP (Westmark
andMalter 2007), and anmRNA target we confirmed in vivo, Rhoa
(Chen et al. 2003; Fig. 6B), which, respectively, regulate six and
fourmetabolites. APP plays a central role in synaptic functions and
Alzheimer’s disease (Kamenetz et al. 2003), and genetic dysregu-
lations of the cytoskeleton-regulators RHOA family are linked to ID
(Benarroch 2007). These data suggest that alterations of the levels
of RHOA and APP proteins in the absence of FMRPmay have direct
neuronal consequences. Interestingly, APP and RHOA interact
with two important enzymes in our iMIM network (Fig. 5; Table 2)
involved in acetylcholine metabolism: respectively, acetylcholine
esterase (ACHE) (Fig. 7; Cottingham et al. 2002), the enzyme
degrading Ach into acetate and choline, and phospholipase D1
(PLD1) (Fig. 7; Klein 2005), which provides free choline for the
synthesis of Ach in the brain. Our iMIM analysis also reveals that
another key enzyme involved in acetylcholine metabolism [cho-
line O-acetyltransferase (CHAT)] is pivotal (Figs. 3, 7; Table 2).
These data support the involvement of the cholinergic system in
FXS, suggested by the fact that molecules
targeting the cholinergic pathway rescue
some behavioral and molecular pheno-
types in the FXSDrosophilamodel (Chang
et al. 2008).
In addition, other pathways involv-
ing proteins encoded by poorly char-
acterized FMRP mRNA targets are also
highlighted by the network approach.
First, the mRNA encoding the neuronal
calcium-binding protein Calbindin1
(CALB1) was shown to bind FMRP by fil-
ter binding assay (Miyashiro et al. 2003),
and we provide evidence that the in-
teraction occurs in vivo in brain (Fig. 6).
Interestingly, Calbindin1 directly targets
myo-inositol monophosphatase (IMPA1)
in spines and dendrites of cerebellar
Purkinje neurons (Schmidt et al. 2005).
Deregulations of CALB1 levels might,
therefore, directly drive the cerebellar de-
crease in myo-inositol. Intriguingly, the
Calb1-KO cerebellum displays the similar
Purkinje cell spine dysgenesis phenotype
as the Fmr1-KO mouse (Vecellio et al.
2000), reinforcing the potential involve-
ment of CALB1 in FXS. Also, deficits in
the neurotransmitters GABA and gluta-
mate are connected to FMRP by pivotal
mRNA targets (Fig. 5; Table 2; Supple-
mental Table S3) encoding, respectively, the GABAB receptor sub-
units GABRD and GABRP (Miyashiro et al. 2003) and the NMDA-
glutamate receptor GRIN1 and GRIN2B (Schu¨tt et al. 2009). It is
interesting to underline thatmutations in bothGRIN1 andGRIN2B
are involved in forms of syndromic or nonsyndromic ID (Gecz
2010). Finally, the iMIM network highlights pivotal roles for the
mRNA encoding the G-protein regulator GNAI2 (Miyashiro et al.
2003), which is involved in neuronal development (Shinohara
et al. 2004), and the mRNA encoding the transcription factor
Forkhead box class O3 (FOXO3), which influences behavioral
processes linked to anxiety and depression (Polter et al. 2009). Our
iMIM strategy usefully brings to light signaling pathways that are
likely to be directly involved in the pathophysiology of FXS.
Conclusions
Our study defines for the first time a robust metabolic phenotype
(metabotype) associated with Fmr1-deficiency, involving several
neurotransmitters and the readjustment of brain biochemical
pathways, suggesting that FXS may not only be a mental disease
restricted to alterations in local neuronal functions but also
a metabolic disease. Since FMRP affects mRNA translation and
protein-protein interaction networks, we developed a network
biology method which we named integrated metabolome and
interactomemapping, connecting the causativemutation in FMR1
to its metabotype via the interactome. Thus, we demonstrated that
FMRP impacts a variety of transduction cascades, and metabolic
and signaling pathways which could be shared with other diseases
(e.g., Alzheimer’s disease, other IDs). The key regulatory proteins
identified by iMIMwere functionally validated in vivo by UV-CLIP
and constitute ideal candidate drug targets for further therapeutic
development (Yildirim et al. 2007). Finally, interactome-mapping
Figure 7. Schematic metabolic map of Fmr1-deficiency in cortex and cerebellum. Astrocytes and
neurons cooperatemetabolically for neuronal energy fueling and biosynthesis of neurotransmitters, and
this cooperation seems compromised in the Fmr1-null brain. Glucose, lactate, and acetoacetate are
neuronal energy substrates (framed in pink) which contribute to replenish acetyl-coA stores to fuel the
tricarboxylic acid cycle. Glutamate and GABA can enter the TCA cycle via conversion upstream of or
downstream from the intermediate metabolite alpha-ketoglutarate (aKG). Metabolites affected by
Fmr1-deficiency are represented in blue if decreased and red if increased. Metabolites acting as neu-
rotransmitters are represented in yellow frames. (NAA) N-acetyl-aspartate, (NAAG) N-acetyl-aspartyl-
glutamate, (GAD65) glutamate dehydrogenase, (CHAT) choline O-acetyltransferase, (ACHE) acetyl-
cholinesterase.
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of metabolic phenotypes is easily amenable to the study of other
monogenic disorders or polygenic disorders and should contribute
to understanding metabolomic signatures in various mechanistic
and signaling contexts.
Methods
Animal handling and sample collection
Fmr1-knockout mice of the FBV strain and their wild-type litter-
mates were used in this study. Genotypes were determined by PCR
analysis of DNA extracted from tails, according to the original
paper describing these animals (The Dutch-Belgian Fragile X
Consortium 1994). The day of birth was considered as post-natal
day 0. For western blot and immunohistochemistry, wild-type FVB
mice were sacrificed post-natally at various time points, the brain
was quickly removed from the skull and stored at80°C for further
analysis. For 1H-MAS NMR analysis, the study was restricted to
males aged 11–12 d. Animals were killed by cervical dislocation.
The brain was then quickly removed from the skull and dissected,
always in the same sequence (first cerebellum, followed by cortex,
hippocampus, and striatum). These operations were typically
processed within 5–10 min to limit post-mortem changes in the
metabolite content of the samples. Right and left samples of each
anatomical region were then immediately snapped-frozen in
liquid nitrogen and stored at 80°C until further analysis. A
total of n = 10 knock-out and n = 10 wild-type animals were
analyzed in this study.
Western blot and immunohistochemistry
Brain sampleswere thawed on ice, weighed, and extracted in 2mL/
100 mg of cold extraction buffer (20 mM Tris pH 7.4, 2.5 mM
MgCl2, 150 mM NaCl, 0.5% NP40) supplemented with anti-
protease cocktail (Roche). Lysates were sonicated on ice twice for
20 sec and centrifuged at 10,000 g for 10 min at 4°C. Supernatant
was collected, and protein content was determined by spectrom-
etry at 280 nm using Bradford reagent (Biorad). 25 mg of proteins
were loaded on an 11% SDS-PAGE, and western blotting was per-
formed as described (Davidovic et al. 2006), using the mAb1C3
anti-FMRP monoclonal antibody (Devys et al. 1993). For immu-
nohistochemistry, a 12-d- old wild-type mouse was deeply anes-
thetized with isoflurane and transcardially perfused with 4%
paraformaldehyde in PBS. The brain was removed, post-fixed
overnight, transferred to cryoprotective solution (HistoPrep, Fisher
Scientific), frozen, and serially cut into longitudinal sections (15
mm) with a Leica CM1900 cryostat. Immunohistochemistry was
performedwith the anti-FMRPmAb1C3 antibody revealed by DAB
staining using the Vectastain Elite ABC kit, according to the
manufacturer’s protocol, as described (Devys et al. 1993). Sections
were finally counterstained with cresyl-violet and observed with
a Leica DMD108 digital microscope.
1H HR-MAS NMR spectroscopy
All NMR experiments were carried out on a Bruker Avance spec-
trometer (Bruker GmbH) operating at 700 MHz. About 10 mg of
brain tissue (1mm3) was filled in a HR-MASNMR rotor and spun at
4 kHz for one-dimensional analysis with a high-resolution Magic
Angle Spinning probe operating at 4°C. To record low-noise, high-
resolution spectral data, samples were spun for a 25-min acquisi-
tion to accumulate 1024 transient scans. One- and two-dimen-
sional NMR structural assignment was performed using data from
the literature, HMDB (http://www.hmdb.ca/) and S-Base (Bruker
GmbH).
Data import and pattern recognition
1H HR-MAS NMR spectra were referenced to the center of the ala-
nine doublet at d1.48, phased and baseline-corrected using the
Topspin 1.3 interface (Bruker GmbH). They were reduced over the
chemical shift range of 0.49 to 9.59 ppm with exclusion areas
around residual water signal (4.61–4.99 ppm) and its magic angle
spinning side band 0.40 to –0.19 ppm) using AMIX (Bruker
GmbH) to 10,000 103 ppmwide regions (buckets), and the signal
intensity in each region was integrated. The corresponding bucket
tableswere then exported to Simca-P12 (Umetrics),Matlab, andR for
statistical analyses after row profile (constant sum) normalization.
Multivariate statistics
Principal component analyses (PCA) were run to check the ho-
mogeneity of NMR spectra and exclude outliers. Orthogonal par-
tial least-squares discriminant analyses were run to discriminate
the experimental groups of mouse brains by adding a supplemen-
tary data matrix Y, containing classification information about
factors such as genetics and brain region.
Metabolite Set Enrichment Analysis
To identify themost significantly affectedmetabolic pathways, the
metabolites affected by Fmr1-deficiency were analyzed by Metab-
olite Set Enrichment Analysis approach (Xia and Wishart 2010;
Pontoizeau et al. 2011), defined as an extension of Gene Set En-
richment Analysis (Subramanian et al. 2005), to test for metabolic
pathways enrichment. For each brain region and each metabolic
pathway, a 2 3 2 contingency table was built by counting the
corresponding number of metabolites. An exact Fisher test was
then applied to statistically assess the overrepresentation of dis-
criminant metabolites according to the whole metabolome, i.e.,
the whole set of metabolites assumed to exist in the brain, ac-
cording to Rivals et al. (2007). To control the false discovery rate
associated with multiple testing, the exact Fisher test P-value was
finally adjusted using the Benjamini and Hochberg procedure.
Only the adjusted P-value is presented in the tables.
Integrated metabolome and interactome mapping
of FMR1-deficiency metabotypes
To functionally connect the FMR1 gene deficiency in FXS to the
candidate biomarker metabolites identified by OPLS-DA analysis,
a bottom-up approach, combining scientific knowledge extracted
from public databases and the literature, was devised to build the
integratedmetabolome and interactomemapping network related
to FMR1-KO. For standardization purpose, human official genes
and proteins symbols were used throughout the iMIM approach.
One part of the network is composed of the FMR1 gene and the
biomarkers ligand receptors (glutamate, GABA, alanine, taurine,
acetylcholine, and aspartate), but also the target enzymes known
to be involved in the metabolism of the biomarkers. Lists of the
283 receptors and target enzymes linked to the 25 metabolites
were extracted, respectively, from the KEGG database (Kanehisa
et al. 2008) and NeuroDB, a database of receptor-ligand inter-
actions developed by Yale University (http://senselab.med.yale.
edu/NeuronDB/). To connect FMR1 dysfunction to the 25 distinct
biomarker metabolites, the network integrates metabolite-enzyme
interactions (mei) based on the comprehensivemetabolic network
defined in KEGG but also metabolite-receptor interactions (mri)
available in the comprehensive receptor-ligand databaseNeuroDB.
FMR1 and this set of receptors and target enzymes were next
functionally connected through protein-protein interaction (ppi)
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inferred from a comprehensive mammalian interactome com-
prising 8788 proteins and 70,897 interactions (Navratil et al.
2009). According to the functional importance of FMRP in mRNA
translation regulation mediated by direct binding of FMRP to its
target mRNA, the FMR1 network was also completed with pro-
tein-RNA interactions (pri). A database of 241 interactions, in-
cluding nonredundant pri (n = 214) and ppi (n = 27) between FMRP
and its target mRNA or its binding partners, was extensively cu-
rated from the literature (see Supplemental Table S1 for a complete
list of references). The final network includes FMR1, 42 target en-
zymes and three receptors, 117 target mRNAs of FMRP (encoding
one enzyme SOD1 and seven receptors, notably GABRP, GABRD,
and GRIK5), and 25 metabolites.
Gene Set Enrichment Analysis
Gene Set Enrichment Analysis was based on Gene Ontology (bi-
ological process) and KEGG, and the Exact Fisher’s statistical pro-
cedure (Rivals et al. 2007) was used to characterize overrepresented
functions associated with mRNA targets of FMRP and genes in-
cluded in the FMR1 knock-out network as compared to the entire
GO biological process annotation of the proteome.
Topological analysis of the iMIM knowledge network
The knowledge network was mathematically formalized as an
undirectedmultilabeled graphGm,n = (Vm,En) composed of three
node types, Vm, where m = {‘‘proteins,’’ ‘‘mRNA,’’ ‘‘metabolites’’},
and four functional edges, En,where n = {‘‘ppi,’’ ‘‘pri,’’ ‘‘mei,’’ ‘‘mri’’}.
A few definitions are provided as follows:
Shortest Path (sp): To understand how FMR1-deficiency
propagates throughout the functional knowledge network, short-
est paths from FMR1 to the target enzymes associated with each
candidate biomarker metabolite were measured. The shortest path
problem corresponds to finding a path between two nodes such
that the sum of the weights of its constituent edges is minimized.
The shortest paths—also called geodesics—are computed here by
using a breadth-first search in the FMR1-KO iMIM network. In the
particular case of the iMIMnetwork, edgeweights are not used, i.e.,
all edge weights equal one. The shortest path length (spl) between
two nodes is the distance defined by the number of hops between
these two nodes within the FMR1 knockout functional knowledge
network. For example, FMR1 is at a one-hop distance from a target
enzyme if they are separated by only one edge (for instance, FMR1
is directly connected to SOD1 by a pro-
tein-RNA interaction).
Pivotal Betweenness (pb): To quan-
titatively rank the importance of pivotal
molecules into the interaction network,
a new network metric, based on a be-
tweenness centrality measure (Freeman
1977) was defined, called the pivotal be-
tweenness. For each node, the between-
ness [b(v)] canbedefinedby thenumber of
shortest paths going through a node v and
is normalized by twice the total number of
protein pairs in the network [n 3 (n1)].
b vð Þ = 1
n3 n  1ð Þ 3 +i;j;v2V
spij vð Þ
spij
In the equation used to compute the be-
tweenness, b(v), for a node v, spij is the
number of shortest paths going from
node i to j, i and j 2 V, and spij(v) is the
number of shortest paths from i to j that pass through the pivotal
node. The pivotal betweenness is a particular case of betweenness,
with i being FMR1, and j the list of target enzymes. A high pivotal
betweenness value for a given molecule indicates that this pivotal
molecule is highly central to the metabolic biomarker functional
path.
Metabolite confirmation assays
Total proteins from Fmr1-KO and WT littermates were extracted
from cortex and cerebellumusing lysis buffer (10mMTris pH 7.4, 5
mM EDTA, 0.1% SDS, 0.5% deoxycholate, 0.5% NP40) and
quantified with a Bradford assay according to the manufacturer’s
recommendations (Biorad). Protein levels in each sample were
further verified by Coomassie-blue staining. Glutamate levels were
then quantified in 40 mg of total protein content using a glutamate
enzymatic assay according to themanufacturer’s protocol (BioAssay
Systems). GABA levels were quantified in 100 mg of proteins using
a GABA ELISA kit (Labor Diagnostika Nord). Data (n = 9 animals per
genotype) were analyzed with a one-tailed Mann-Whitney non-
parametric statistical test (U-test), and box plots were constructed
using the Prism4 software.
UV-crosslinking and immunoprecipitation mRNA interaction
confirmation assay
To isolate mRNAs associated with FMRP in vivo, UV-crosslinking
and immunoprecipitations were performed with total brain ex-
tracts from 12-d-old Fmr1-KO and WT mice, using the protocol
described previously (Ule et al. 2005), and the R60 polyclonal an-
tibody directed against the C terminus of FMRP, whose character-
ization is detailed in Supplementary Material (Supplemental Fig.
S1). For each assay, 10 mg of affinity-purified anti-FMRP antibody
was used to immunoprecipitate 1 mg of brain lysate. Approxi-
mately 1/100th of the homogenate and 1/20th of the immuno-
precipitate were loaded on an 11% SDS-PAGE gel. Proteins trans-
ferred onto a 0.45 mm nitrocellulose membrane were revealed
using the mAb1C3 recognizing FMRP (Devys et al. 1993) and the
3Fx antibody recognizing both FXR1P and FXR2P (Khandjian et al.
1998). mRNA was extracted from brain homogenate and immu-
noprecipitates using TRIzol reagent (Invitrogen) according to the
manufacturer’s protocol and reverse-transcribed (RT) using the
SuperscriptScriptII RT-PCR system (Invitrogen). RT products were
subjected to polymerase chain reaction (PCR), using a PCR Master
Table 3. List and details of primers used to detect mRNAs associated in vivo with FMRP
immunoprecipitates
Target
mRNA
Primer
name 59 39sequence
Amplicon
size
Cycle
number Reference
Fmr1 F GCTCCAACAGAGGAAGAGGG 306 bp n = 35 (Bechara et al. 2009)
R GGGTACTCCATTCACCAGCGG
Mtap1b F TCCGATCGTGGGACACAAACCTG 228 bp n = 45 (Edbauer et al. 2010)
R AGCACCAGCAGTTTATGGCGGG
Sod1 F ACCATCCACTTCGAGCAGAA 196 bp n = 25 (Bechara et al. 2009)
R AGTCACATTGCCCAGGTCTC
Rhoa F TGGTTGGGAACAAGAAGGAC 233 bp n = 45 Primer3
R TGAGGCACCCAGACTTTTTC
Calb1 F GAAGGAAAGGAGCTGCAGAA 212 bp n = 50 Primer3
R TTCCTCGCAGGACTTCAGTT
Tubb3 F CGAGACCTACTGCATCGACA 151 bp n = 35 Primer3
R CATTGAGCTGACCAGGGAAT
Pgk1 F GAAGGGGAAGCGGGTCGTGATG 206 bp n = 35 (Edbauer et al. 2010)
R GCAGCAACTGGCTCTAAGGAGTACTTG
Primer sequences originated either from literature or were designed using the Primer3 webtool.
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Kit (Promega) and primers, detailed in Table 3, specific for Fmr1,
Sod1, Mtap1b, Rhoa, Calb1, Tubb3, and Pgk1 mouse cDNAs. The
PCR program consisted in 10 min of initial denaturation at 95°C,
followed by n cycles of: 30 sec at 95°C, 30 sec at 58°C, 30 sec at
72°C, and a final elongation step of 10 min at 72°C. PCR products
were visualized on a 1.5% TAE agarose gel, and amplicon size was
verified using the 1 Kb+ DNA ladder (Invitrogen).
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